Anti-Tumor Immunity in Response to a Modified Vaccine Strain Measles Virus

Project: Research project

Description

DESCRIPTION (provided by applicant): My long-term career goal is to become an independent translational investigator in thoracic oncology. I am planning to focus my laboratory-based research on the characterization and therapeutic modification of the immunological tumor microenvironment of thoracic malignancies. Moreover, I anticipate investigating new promising therapeutic strategies for these patients in clinical trials. The caree development and research plans outlined in this proposal will provide me with the skill set necessary to accomplish these goals. Thoracic malignancies are very common and deadly diseases. However, highly effective treatment strategies are lacking. The therapeutic use of oncolytic viruses, such as modified vaccine strain measles viruses (MV), to induce tumor cell destruction represents a very attractive alternative. Despite some very promising clinical outcomes in patients with refractory ovarian cancer the mechanisms by which MV limits tumor growth remain poorly understood. Possible effects include direct viral oncolysis and immune mediated tumor cell destruction targeting viral and/or tumor antigens. Suboptimal viral replication and pre-existing neutralizing anti-viral antibodies implicate immune mediated destruction rather than oncolysis. Herein we propose to investigate the effects of a modified MV carrying the human gene for the sodium iodine symporter (NIS) on local and systemic anti-tumor and antiviral immunity. We will conduct a phase I study testing the intrapleural administration of up to six cycles of MV-NIS in patients with MPM. Secondary endpoints, specifically progression free survival will be measured in an expanded MTD cohort for the preliminary assessment of the effect of MV-NIS on tumor progression. Correlative studies will non-invasively measure viral replication using sequential I123 SPECT/CT scanning and analyze the local (pleural fluid via permanent pleural catheter) and systemic (blood) anti-tumor and anti-MV immunity throughout the trial. We anticipate that the results of these investigations will enhance our understanding of the mechanisms of MV virotherapy in thoracic malignancies, result in improved treatment protocols and help to expand the therapeutic use of modified vaccine from MPM to other thoracic malignancy. Most importantly, the proposed clinical trial with the associated correlative studies, mentorship and integrated coursework will provide me with the clinical trial experience to accomplish my career goal of becoming an independent translational investigator in thoracic Oncology.
StatusFinished
Effective start/end date8/1/127/31/16

Funding

  • National Institutes of Health: $164,160.00
  • National Institutes of Health: $164,160.00
  • National Institutes of Health: $164,160.00
  • National Institutes of Health: $164,160.00

Fingerprint

Measles virus
Immunity
Vaccines
Thorax
Neoplasms
Clinical Trials
Therapeutic Uses
Research Personnel
Oncolytic Viruses
Viral Antibodies
Symporters
Personal Autonomy
Mentors
Tumor Microenvironment
Viral Tumor Antigens
Clinical Protocols
Neutralizing Antibodies
Research
Iodine
Ovarian Neoplasms

ASJC

  • Medicine(all)